Emerging treatments

A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Benson DM Jr et al. Clin Cancer Res. 2015 May 21. pii: clincanres.0304.2015. [Epub ahead of print]. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Noonan KA et al. Sci Transl Med. 2015 May 20;7(288):288ra78. doi: 10.1126/scitranslmed.aaa7014.…

Biology and genetics

Lenalidomide augments actin remodelling and lowers NK cell activation thresholds. Lagrue K et al. Blood. 2015 May 22. pii: blood-2015-01-625004. [Epub ahead of print]. CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in Multiple Myeloma. Yousef S et al. Hum Vaccin Immunother. 2015 May 22:0. [Epub ahead of print]. MicroC3: an ex vivo…

Supportive care

Comparison of Percutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Single Level Vertebral Compression Fractures: A Meta-analysis of the Literature. Wang H et al. Pain Physician. 2015 May-Jun;18(3):209-22. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Diel IJ et al. Eur J Cancer. 2015 May 11. pii: S0959-8049(15)00373-1. doi: 10.1016/j.ejca.2015.04.017.…

General

Multiple myeloma: new uses for available agents, excitement for the future. Anderson KC. J Natl Compr Canc Netw. 2015 May;13(5 Suppl):694-6. Expanding role of lenalidomide in hematologic malignancies. Ghosh N et al. Cancer Manag Res. 2015 May 2;7:105-19. doi: 10.2147/CMAR.S81310. eCollection 2015. A Rare Variant of Multiple Myeloma; Non-Secretory Myeloma with diffuse osteolytic lesions. Sultan S et al. Gulf J Oncolog. 2015 May;1(18):28-31. Mapping Functions in…

Complications of myeloma and its treatments

Serous macular detachment, yellow macular deposits, and prominent middle limiting membrane in multiple myeloma. Dogan B et al. Ther Clin Risk Manag. 2015 Apr 30;11:683-9. doi: 10.2147/TCRM.S79232. eCollection 2015. Contribution of Clostridium difficile infection to the development of lower gastrointestinal adverse events during autologous stem cell transplantation. Apewokin S et al, Transpl Infect Dis. 2015 May 19. doi: 10.1111/tid.12403. [Epub ahead of…

Current treatments

Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. Poenisch W et al. J Cancer Res Clin Oncol. 2015 May 15. [Epub ahead of print]. High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. Wildes TM et al. Bone Marrow Transplant. 2015 May 11. doi: 10.1038/bmt.2015.106. [Epub…

Diagnostic tests and prognostic indicators

Plasma cell morphology in multiple myeloma and related disorders. Ribourtout B et al. Morphologie. 2015 Apr 18. pii: S1286-0115(15)00021-1. doi: 10.1016/j.morpho.2015.02.001. [Epub ahead of print]. Proteomic Analysis for Finding Serum Pathogenic Factors and Potential Biomarkers in Multiple Myeloma. Zhang HT et al. Chin Med J (Engl). 2015 20th Apr;128(8):1108-1113. doi: 10.4103/0366-6999.155112. Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of…

Related conditions

Clinical and Prognostic Differences among Patients with Light Chain Deposition Disease, Myeloma Cast Nephropathy and Both. Zand L et al. Leuk Lymphoma. 2015 Apr 10:1-27. [Epub ahead of print]. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Afrough A et al. Biol Blood Marrow Transplant. 2015 Apr 2. pii: S1083-8791(15)00225-6.…

Emerging treatments

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. Laubach JP et al. Clin Cancer Res. 2015 Apr 15. pii: clincanres.3190.2015. [Epub ahead of print]. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Chon HJ et al. Front Pharmacol. 2015 Mar 31;6:70. doi: 10.3389/fphar.2015.00070. eCollection 2015. Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat…

Biology and genetics

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Walker BA et al. Nat Commun. 2015 Apr 23;6:6997. doi: 10.1038/ncomms7997. Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1. Fujiwara S et al. Exp Hematol Oncol. 2015 Apr 21;4:12. doi: 10.1186/s40164-015-0008-z. eCollection 2015. Dutcher bodies in multiple myeloma are highly associated with translocation t(4;14) and IgA…